Intravenous immunoglobulin for multiple sclerosis
Record ID 32006000107
English
Authors' objectives:
Intravenous immunoglobulin (IVIG) therapy is used to provide passive immunity or to alter the immune response by increasing an individual's antibody titer and antigen-antibody reaction potential. IVIG has been investigated as a treatment for patients with multiple sclerosis (MS), with the goal of slowing the progression of disease and reducing the severity of symptoms associated with relapsing-remitting multiple sclerosis and secondary-progressive multiple sclerosis.
Authors' methods:
Review
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=2180
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Immunoglobulins, Intravenous
- Multiple Sclerosis
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
HAYES, Inc.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.